ConductScience.org, home

Paper41018484

Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Rojas M and 7 others. Explor Target Antitumor Ther, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Papers, record 41018484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41018484

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
PubMed
Journal
Explor Target Antitumor Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-10-01
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rojas MMariamhttps://orcid.org/0009-0001-7837-020X
2Manzi MMalenahttps://orcid.org/0000-0002-1709-0685
3Madurga SSergiohttps://orcid.org/0000-0002-8135-7057
4García Velásquez FEFernando Enrique
5Romero MAMaira Alejandra
6Marín SSilviahttps://orcid.org/0000-0003-0693-2207
7Cascante MMartahttps://orcid.org/0000-0002-2062-4633
8Maurel JJoanhttps://orcid.org/0000-0002-9413-5592

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References97

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129395328CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness.Cell2018https://conductscience.org/library/papers/29395328PubMed
232047001BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.Clin Cancer Res2020https://conductscience.org/library/papers/32047001PubMed
336307056Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2023https://conductscience.org/library/papers/36307056PubMed
437069167Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis.Nat Commun2023https://conductscience.org/library/papers/37069167PubMed
534764457Fibroblast pyruvate carboxylase is required for collagen production in the tumour microenvironment.Nat Metab2021https://conductscience.org/library/papers/34764457PubMed
625119024Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.Nature2014https://conductscience.org/library/papers/25119024PubMed
739820673An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.Clin Cancer Res2025https://conductscience.org/library/papers/39820673PubMed
838273133Publisher Correction: Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis.Nature2024https://conductscience.org/library/papers/38273133PubMed
939475591Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.J Clin Oncol2025https://conductscience.org/library/papers/39475591PubMed
1033238129Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation.Cell Rep2020https://conductscience.org/library/papers/33238129PubMed
1139699311Lysosomal-Mitochondrial Interaction Promotes Tumor Growth in Squamous Cell Carcinoma of the Head and Neck.Mol Cancer Res2025https://conductscience.org/library/papers/39699311PubMed
1229728604Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.Nat Commun2018https://conductscience.org/library/papers/29728604PubMed
1331851936Systems-Genetics-Based Inference of a Core Regulatory Network Underlying White Fat Browning.Cell Rep2019https://conductscience.org/library/papers/31851936PubMed
1438052910Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.Nat Med2024https://conductscience.org/library/papers/38052910PubMed
1529949778Targeting a Sirt5-Positive Subpopulation Overcomes Multidrug Resistance in Wild-Type Kras Colorectal Carcinomas.Cell Rep2018https://conductscience.org/library/papers/29949778PubMed
1626457759The consensus molecular subtypes of colorectal cancer.Nat Med2015https://conductscience.org/library/papers/26457759PubMed
1729891662Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer.Proc Natl Acad Sci U S A2018https://conductscience.org/library/papers/29891662PubMed
1831439581A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.Clin Cancer Res2019https://conductscience.org/library/papers/31439581PubMed
1938216672TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.Oncogene2024https://conductscience.org/library/papers/38216672PubMed
2031825825CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.Cell Rep2019https://conductscience.org/library/papers/31825825PubMed

See all 97 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42941901Metabolic Dysfunction and T-Cell Exhaustion in Colorectal Cancer: Mechanisms, Microenvironment Remodeling, and Therapeutic Opportunities.Int J Mol Sci2026https://conductscience.org/library/papers/42941901PubMed
42910173Identification of Immuno-Diagnostic and Therapeutic Markers in Tumors and Inflammatory Diseases Based on Single-Cell and Machine Learning Methods.Hum Mutat2026https://conductscience.org/library/papers/42910173PubMed
42528626Convergent adaptive architectures linking chemoresistance and radioresistance in chemoradiotherapy: a systems-level perspective.Front Oncol2026https://conductscience.org/library/papers/42528626PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41018484

GET https://conductscience.org/api/papers/v1/41018484/references?page=2